Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Respectable Supreme Court of India has taken the step towards the modernization of judicial services…
Respectable West Bengal Chief Minister Suvendu Adhikari has announced the Annapurna Bhandaar scheme across the…
To boost the manufacturing India is planning to launch the Made in India Brand Scheme…
Respectable President of India Shri. Droupadi Murmu has presented the National Florence Nightingale Awards 2026…
The Government of India ha announced the nationwide rollout of the Viksit Bharat - Guarantee…
India has taken major step towards the healthier future with the launch of Sehat Mission…